These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 21250983

  • 1. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a meta-analysis.
    Huang G, Xu JB, Liu JX, He Y, Nie XL, Li Q, Hu YM, Zhao SQ, Wang M, Zhang WY, Liu XR, Wu T, Arkin A, Zhang TJ.
    Eur J Clin Invest; 2011 Jul; 41(7):719-33. PubMed ID: 21250983
    [Abstract] [Full Text] [Related]

  • 2. The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials.
    Zhang Y, Zhang P, Mu Y, Gao M, Wang JR, Wang Y, Su LQ, Hou YL.
    Clin Pharmacol Ther; 2010 Oct; 88(4):521-31. PubMed ID: 20811347
    [Abstract] [Full Text] [Related]

  • 3. [Are ACE inhibitors and angiotensin receptor blockers useful in the treatment of atrial fibrillation?].
    Raatikainen MJ, Huikuri HV.
    Duodecim; 2003 Oct; 119(16):1505-7. PubMed ID: 14535023
    [No Abstract] [Full Text] [Related]

  • 4. Drug therapy for atrial fibrillation.
    Conway EL, Musco S, Kowey PR.
    Cardiol Clin; 2009 Feb; 27(1):109-23, ix. PubMed ID: 19111768
    [Abstract] [Full Text] [Related]

  • 5. Role of renin-angiotensin system inhibitors in atrial fibrillation.
    Disertori M, Latini R, Maggioni AP.
    J Cardiovasc Med (Hagerstown); 2011 May; 12(5):374; author reply 375. PubMed ID: 21451337
    [No Abstract] [Full Text] [Related]

  • 6. Focus on renin-angiotensin system modulation and atrial fibrillation control after GISSI AF results.
    Durin O, Pedrinazzi C, Inama G.
    J Cardiovasc Med (Hagerstown); 2010 Dec; 11(12):912-8. PubMed ID: 20729747
    [Abstract] [Full Text] [Related]

  • 7. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation.
    Richter B, Derntl M, Marx M, Lercher P, Gössinger HD.
    Am Heart J; 2007 Jan; 153(1):113-9. PubMed ID: 17174648
    [Abstract] [Full Text] [Related]

  • 8. The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials.
    Madrid AH, Peng J, Zamora J, Marín I, Bernal E, Escobar C, Muños-Tinoco C, Rebollo JM, Moro C.
    Pacing Clin Electrophysiol; 2004 Oct; 27(10):1405-10. PubMed ID: 15511250
    [Abstract] [Full Text] [Related]

  • 9. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM, Sanoski CA, Spinler SA.
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [Abstract] [Full Text] [Related]

  • 10. Renin-angiotensin system inhibitors prevent the recurrence of atrial fibrillation: a meta-analysis of randomized controlled trials.
    Han M, Zhang Y, Sun S, Wang Z, Wang J, Xie X, Gao M, Yin X, Hou Y.
    J Cardiovasc Pharmacol; 2013 Oct; 62(4):405-15. PubMed ID: 23921300
    [Abstract] [Full Text] [Related]

  • 11. Angiotensin converting enzyme inhibitor and angiotensin receptor blockade use in relation to outcomes in anticoagulated patients with atrial fibrillation.
    Lip GY, Frison L, Grind M.
    J Intern Med; 2007 Jun; 261(6):577-86. PubMed ID: 17547713
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have no beneficial effect on ablation outcome in chronic persistent atrial fibrillation.
    Zheng B, Kang J, Tian Y, Tang R, Long D, Yu R, He H, Zhang M, Shi L, Tao H, Liu X, Dong J, Ma C.
    Acta Cardiol; 2009 Jun; 64(3):335-40. PubMed ID: 19593943
    [Abstract] [Full Text] [Related]

  • 13. [Unsatisfactory results of upstream therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for the prevention of recurrent atrial fibrillation].
    Disertori M, Zeni P, Quintarelli S, Bonmassari R.
    G Ital Cardiol (Rome); 2010 Nov; 11(11):829-34. PubMed ID: 21348320
    [Abstract] [Full Text] [Related]

  • 14. [Drugs for heart rate control and non-antiarrhythmic drugs in atrial fibrillation].
    Chávez LL.
    Arch Cardiol Mex; 2007 Nov; 77 Suppl 2():S2-54-S2-58. PubMed ID: 17972380
    [Abstract] [Full Text] [Related]

  • 15. Impact of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the long-term outcome after pulmonary vein isolation for paroxysmal atrial fibrillation.
    Klemm HU, Heitzer T, Ruprecht U, Meinertz T, Ventura R.
    Cardiology; 2010 Nov; 117(1):14-20. PubMed ID: 20881389
    [Abstract] [Full Text] [Related]

  • 16. The impact of suppressing the renin-angiotensin system on atrial fibrillation.
    Kalus JS, Coleman CI, White CM.
    J Clin Pharmacol; 2006 Jan; 46(1):21-8. PubMed ID: 16397280
    [Abstract] [Full Text] [Related]

  • 17. Rhythm control for atrial fibrillation: non-channel antiarrhythmic drugs are en vogue.
    Van Gelder IC.
    Cardiovasc Res; 2007 Apr 01; 74(1):8-10. PubMed ID: 17336952
    [No Abstract] [Full Text] [Related]

  • 18. Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure.
    Aksnes TA, Flaa A, Strand A, Kjeldsen SE.
    J Hypertens; 2007 Jan 01; 25(1):15-23. PubMed ID: 17143167
    [Abstract] [Full Text] [Related]

  • 19. Inefficiency of renin-angiotensin inhibitors in preventing atrial fibrillation in patients with a normal heart.
    Fazio G, Pizzuto C, Sutera L, Guttilla D, Di Gesaro G, Cascio C, Novo G, Assennato P, Novo S.
    Minerva Cardioangiol; 2007 Jun 01; 55(3):311-5. PubMed ID: 17534249
    [Abstract] [Full Text] [Related]

  • 20. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention.
    Savelieva I, Kakouros N, Kourliouros A, Camm AJ.
    Europace; 2011 Mar 01; 13(3):308-28. PubMed ID: 21345926
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.